Information Provided By:
Fly News Breaks for September 28, 2015
OMED
Sep 28, 2015 | 08:13 EDT
After spending time with management, Jefferies analyst Brian Abrahams says he remains convinced that the market is underappreciating OncoMed's pipeline and partnerships. He expects share upside over the next 18 months as the company's programs mature. The analyst keeps a Buy rating on the stock with a $32 price target.
News For OMED From the Last 2 Days
There are no results for your query OMED